Trial Outcomes & Findings for Effects of Statin Therapy on Vascular Properties and Outcomes in Diastolic Heart Failure Patients (NCT NCT00585611)

NCT ID: NCT00585611

Last Updated: 2019-03-26

Results Overview

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

1 participants

Primary outcome timeframe

6 months after initiation of intervention

Results posted on

2019-03-26

Participant Flow

While the record documents 1 participant enrolled in this study, there are no data available to report.

Participant milestones

Participant milestones
Measure
Atorvastatin
Heart failure patients assigned to atorvastatin Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months
Arm 2
Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months placebo: placebo
Overall Study
STARTED
0
0
Overall Study
COMPLETED
0
0
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Effects of Statin Therapy on Vascular Properties and Outcomes in Diastolic Heart Failure Patients

Baseline characteristics by cohort

Baseline data not reported

PRIMARY outcome

Timeframe: 6 months after initiation of intervention

Population: There are no data available

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 6 months after initiation of intervention

Population: There are no data available.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 6 months after initiation of intervention

Population: There are no data available.

Outcome measures

Outcome data not reported

Adverse Events

Atorvastatin

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Arm 2

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Nancy Sweitzer

UW-Madison at time of study

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place